Innovent’s Avastin® Biosimilar (bevacizumab)
Non-small-cell lung carcinoma (NSCLC)
Phase 3 (BLA Filing)
Late 2020 / Early 2021
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Innovent’s Avastin® Biosimilar (bevacizumab) in NSCLC - BLA Filing
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Late 2020/Early 2021
01-2020: 38th Annual J.P. Morgan Global Healthcare Conference (slide 11, 12, 16-19, 29)
~228,820 adults (116,300 men and 112,520 women) in the US will be diagnosed with lung cancer
NSCLC is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses
source - American Lung Society
MECHANISM OF ACTION / RATIONALE
Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.
source - FDA Label (section 12.1)
Updated by HC
#CHRS, #Innovent, #Avastin, #Biosimilar, #bevacizumab, #NSCLC, #BLA
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post